O	0	3	New
O	3	4	-
O	4	9	onset
O	10	16	breast
O	17	27	tenderness
O	28	33	after
O	34	44	initiation
O	45	47	of
B-intervention	48	56	estrogen
I-intervention	57	61	plus
I-intervention	62	71	progestin
I-intervention	72	79	therapy
O	80	83	and
O	84	90	breast
O	91	97	cancer
O	98	102	risk
O	102	103	.

O	104	112	Estrogen
O	113	117	plus
O	118	127	progestin
O	128	135	therapy
O	136	145	increases
O	146	152	breast
O	153	159	cancer
O	160	169	incidence
O	170	173	and
O	174	180	breast
O	181	191	tenderness
O	191	192	.

O	193	200	Whether
O	201	207	breast
O	208	218	tenderness
O	219	225	during
O	226	234	estrogen
O	235	239	plus
O	240	249	progestin
O	250	257	therapy
O	258	260	is
O	261	271	associated
O	272	276	with
O	277	283	breast
O	284	290	cancer
O	291	295	risk
O	296	298	is
O	299	308	uncertain
O	308	309	.

O	310	312	We
O	313	321	analyzed
O	322	326	data
O	327	331	from
O	332	335	the
O	336	341	Women
O	341	342	'
O	342	343	s
O	344	350	Health
O	351	361	Initiative
O	362	370	Estrogen
O	371	372	+
O	373	382	Progestin
O	383	388	Trial
O	388	389	,
O	390	395	which
O	396	406	randomized
B-eligibility	407	421	postmenopausal
I-eligibility	422	427	women
I-eligibility	428	432	with
I-eligibility	433	435	an
I-eligibility	436	442	intact
I-eligibility	443	449	uterus
O	450	452	to
O	453	460	receive
O	461	466	daily
O	467	477	conjugated
O	478	484	equine
O	485	494	estrogens
O	494	495	,
O	496	497	0
O	497	498	.
O	498	501	625
O	502	504	mg
O	504	505	,
O	506	510	plus
O	511	530	medroxyprogesterone
O	531	538	acetate
O	538	539	,
O	540	541	2
O	541	542	.
O	542	543	5
O	544	546	mg
O	547	548	(
O	548	549	n
O	550	551	=
B-intervention-participants	552	556	8506
O	556	557	)
O	557	558	,
O	559	561	or
B-control	562	569	placebo
O	570	571	(
O	571	572	n
O	573	574	=
B-control-participants	575	579	8102
O	579	580	)
O	580	581	.

O	582	584	At
O	585	593	baseline
O	594	597	and
O	598	606	annually
O	606	607	,
O	608	620	participants
O	621	630	underwent
O	631	642	mammography
O	643	646	and
O	647	655	clinical
O	656	662	breast
O	663	674	examination
O	674	675	.

O	676	680	Self
O	680	681	-
O	681	689	reported
O	690	696	breast
O	697	707	tenderness
O	708	711	was
O	712	720	assessed
O	721	723	at
O	724	732	baseline
O	733	736	and
O	737	739	at
O	740	742	12
O	743	749	months
O	749	750	.

O	751	754	The
B-outcome	755	764	incidence
I-outcome	765	767	of
I-outcome	768	776	invasive
I-outcome	777	783	breast
I-outcome	784	790	cancer
O	791	794	was
O	795	804	confirmed
O	805	807	by
O	808	815	medical
O	816	822	record
O	823	829	review
O	830	831	(
O	831	835	mean
O	836	842	follow
O	842	843	-
O	843	845	up
O	846	848	of
O	849	850	5
O	850	851	.
O	851	852	6
O	853	858	years
O	858	859	)
O	859	860	.

O	861	863	Of
O	864	869	women
O	870	877	without
O	878	886	baseline
O	887	893	breast
O	894	904	tenderness
O	905	906	(
O	906	907	n
O	908	909	=
O	910	912	14
O	912	913	,
O	913	916	538
O	916	917	)
O	917	918	,
O	919	932	significantly
O	933	937	more
O	938	946	assigned
O	947	949	to
O	950	957	receive
O	958	968	conjugated
O	969	975	equine
O	976	985	estrogens
O	986	990	plus
O	991	1010	medroxyprogesterone
O	1011	1013	vs
O	1014	1021	placebo
O	1022	1033	experienced
B-outcome	1034	1037	new
I-outcome	1037	1038	-
I-outcome	1038	1043	onset
I-outcome	1044	1050	breast
I-outcome	1051	1061	tenderness
I-outcome	1062	1067	after
I-outcome	1068	1070	12
I-outcome	1071	1077	months
O	1078	1079	(
B-iv-bin-percent	1079	1081	36
I-iv-bin-percent	1081	1082	.
I-iv-bin-percent	1082	1083	1
I-iv-bin-percent	1083	1084	%
O	1085	1087	vs
B-cv-bin-percent	1088	1090	11
I-cv-bin-percent	1090	1091	.
I-cv-bin-percent	1091	1092	8
I-cv-bin-percent	1092	1093	%
O	1093	1094	,
O	1095	1096	P
O	1097	1098	<
O	1099	1100	.
O	1100	1103	001
O	1103	1104	)
O	1104	1105	.

O	1106	1108	Of
O	1109	1114	women
O	1115	1117	in
O	1118	1121	the
O	1122	1132	conjugated
O	1133	1139	equine
O	1140	1149	estrogens
O	1150	1154	plus
O	1155	1174	medroxyprogesterone
O	1175	1180	group
O	1180	1181	,
B-outcome	1182	1188	breast
I-outcome	1189	1195	cancer
I-outcome	1196	1200	risk
O	1201	1204	was
O	1205	1218	significantly
O	1219	1225	higher
O	1226	1228	in
O	1229	1234	those
O	1235	1239	with
O	1240	1243	new
O	1243	1244	-
O	1244	1249	onset
O	1250	1256	breast
O	1257	1267	tenderness
O	1268	1276	compared
O	1277	1281	with
O	1282	1287	those
O	1288	1295	without
O	1296	1297	(
O	1297	1303	hazard
O	1304	1309	ratio
O	1309	1310	,
O	1311	1312	1
O	1312	1313	.
O	1313	1315	48
O	1315	1316	;
O	1317	1319	95
O	1319	1320	%
O	1321	1331	confidence
O	1332	1340	interval
O	1340	1341	,
O	1342	1343	1
O	1343	1344	.
O	1344	1346	08
O	1346	1347	-
O	1347	1348	2
O	1348	1349	.
O	1349	1351	03
O	1351	1352	;
O	1353	1354	P
O	1355	1356	=
O	1357	1358	.
O	1358	1360	02
O	1360	1361	)
O	1361	1362	.

O	1363	1365	In
O	1366	1369	the
O	1370	1377	placebo
O	1378	1383	group
O	1383	1384	,
O	1385	1391	breast
O	1392	1398	cancer
O	1399	1403	risk
O	1404	1407	was
O	1408	1411	not
O	1412	1425	significantly
O	1426	1436	associated
O	1437	1441	with
B-outcome	1442	1445	new
I-outcome	1445	1446	-
I-outcome	1446	1451	onset
I-outcome	1452	1458	breast
I-outcome	1459	1469	tenderness
O	1470	1471	(
O	1471	1472	P
O	1473	1474	=
O	1475	1476	.
O	1476	1478	97
O	1478	1479	)
O	1479	1480	.

O	1481	1484	New
O	1484	1485	-
O	1485	1490	onset
O	1491	1497	breast
O	1498	1508	tenderness
O	1509	1515	during
O	1516	1526	conjugated
O	1527	1533	equine
O	1534	1543	estrogens
O	1544	1548	plus
O	1549	1568	medroxyprogesterone
O	1569	1576	therapy
O	1577	1580	was
O	1581	1591	associated
O	1592	1596	with
O	1597	1606	increased
O	1607	1613	breast
O	1614	1620	cancer
O	1621	1625	risk
O	1625	1626	.

O	1627	1630	The
O	1631	1642	sensitivity
O	1643	1646	and
O	1647	1658	specificity
O	1659	1661	of
O	1662	1665	the
O	1666	1677	association
O	1678	1685	between
O	1686	1692	breast
O	1693	1703	tenderness
O	1704	1707	and
O	1708	1714	breast
O	1715	1721	cancer
O	1722	1726	were
O	1727	1734	similar
O	1735	1737	in
O	1738	1747	magnitude
O	1748	1750	to
O	1751	1756	those
O	1757	1759	of
O	1760	1763	the
O	1764	1768	Gail
O	1769	1774	model
O	1774	1775	.

O	1776	1781	Trial
O	1782	1794	Registration
O	1795	1809	clinicaltrials
O	1809	1810	.
O	1811	1814	gov
O	1815	1825	Identifier
O	1825	1826	:
O	1827	1838	NCT00000611
O	1838	1839	.
